ANALYSIS: With an Obermatt 360° View of 90 (better than 90% compared with alternatives) for 2026, overall professional sentiment and financial characteristics for the stock Royalty Pharma are very positive. The 360° View is based on consolidating four consolidated indicators, with three out of four indicators above average for Royalty Pharma. The consolidated Value Rank has an attractive rank of 93, which means that the share price of Royalty Pharma is on the lower side compared with the typical size in indicators such as revenues, profits, and invested capital. This means the stock price is lower than for 93% of alternative stocks in the same industry. The consolidated Growth Rank has a good rank of 56, which means that the company experiences above-average growth momentum when looking at financial metrics such as revenue, profit, and invested capital growth, as well as stock returns. The company is also safely financed with a Safety Rank of 82. But the professional market sentiment is below average compared with other stock investment alternatives with a Sentiment Rank of only 47. Professional investors are more confident in 53% other stocks. ...read more